Recommendation: Speculative Buy
| Entry Date | Symbol | Recommendation | Entry Price (USD) | Target 1 (USD) | Target 2 (USD) | Holding Duration | Potential Upside* |
|---|---|---|---|---|---|---|---|
| 14 Apr, 25 | CRSP | Speculative Buy | USD 35.91 | USD 37.85 | USD 39.8 | -4 days | 10.8% |
*Potential Upside (%) indicates the expected percentage increase from the Entry Price to the Target 2 Price.
Data Powered by EOD Historical Data (“EODHD”).
CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious human diseases using its Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. Its CRISPR/Cas9 is a gene editing technology that allows for precise directed changes to genomic DNA. The company has a portfolio of therapeutic programs across a range of disease areas, including hemoglobinopathies, immune-oncology and autoimmune, in vivo, and type 1 diabetes. The company's lead product candidate is CASGEVY, an ex vivo CRISPR/Cas9 gene-edited cell therapy for treating patients suffering from transfusion-dependent beta-thalassemia, severe sickle cell disease, and hemoglobinopathies in which a patient's hematopoietic stem and progenitor cells are edited to produce high levels of fetal hemoglobin in red blood cells. It also develops CAR T cell therapies, including CTX112 targeting CD19 and CTX131 targeting CD70 for oncology and autoimmunune indications; CTX310 and CTX320, in vivo gene editing to address the cardiovascular disease by disrupting the validated targets angiopoietin-like protein 3 and lipoprotein; and VCTX211, an allogeneic, gene-edited, hypoimmune stem cell-derived product candidate for the treatment of T1D. It has strategic partnerships with Vertex Pharmaceuticals Incorporated, ViaCyte, Inc., Nkarta, Inc., and Capsida Biotherapeutics. CRISPR Therapeutics AG was incorporated in 2013 and is headquartered in Zug, Switzerland.
Global Clinical Expansion: Over 50 ATCs have been activated globally for CASGEVY®, and more than 50 patients had their cells collected as of 2024-end
Strong Cash Position: Cash and equivalents rose to $1.9 billion by year-end 2024, up from $1.7 billion in 2023, ensuring continued funding for R&D and operations
Reduction in R&D Spending: A drop in R&D expenses to $82.2 million in Q4 2024 from $95.1 million may indicate reduced development activity or cost-cutting
Net Income Reversal: The company reported a $37.3 million net loss in Q4 2024, compared to an $89.3 million net income in Q4 2023
CRISPR Therapeutics faces significant execution risk due to its reliance on early-stage and mid-stage clinical programs, many of which are unproven and subject to complex regulatory, manufacturing, and commercial scalability challenges.
| Entry Price | Support* | Target 1 | Target 2 |
|---|---|---|---|
| 35.91 | 32.45 | 37.85 | 39.8 |
Data Source: REFINITIV, Analysis: StockNextt
*Support can be considered as an indicative stop-loss, and if prices move below that level on closing basis individuals may evaluate exiting the position depending on their risk appetite, previous holdings, and other factors considered. The support and resistance levels may need to be re-evaluated within 4-6 weeks’ time frame depending on the stock price movements from the date of recommendation on the stock.
Commercial Progress with CASGEVY®
CRISPR Therapeutics continues to advance the global launch of CASGEVY® (exagamglogene autotemcel or exa-cel), a gene therapy for sickle cell disease (SCD) and transfusion-dependent beta thalassemia (TDT). As of the end of 2024, over 50 authorized treatment centers (ATCs) have been activated worldwide, and more than 50 patients have completed at least one round of cell collection. The company anticipates a significant uptick in patient cell collection initiations in 2025. CASGEVY is now approved across several key markets, including the U.S., U.K., EU, KSA, Bahrain, Canada, Switzerland, and the UAE. Reimbursement agreements, such as the one recently finalized with NHS England, further solidify the therapy's global accessibility.
Pipeline Expansion and Clinical Milestones
CRISPR Therapeutics is progressing a broad clinical pipeline in 2025, including next-generation CAR T-cell candidates CTX112™ and CTX131™, targeting CD19 and CD70, respectively. These candidates are being evaluated for multiple indications across hematologic malignancies, solid tumors, and autoimmune diseases. Mid-year updates are expected for CTX112, including data in oncology and autoimmune indications. Notably, CTX112 was granted Regenerative Medicine Advanced Therapy (RMAT) designation by the FDA for specific lymphoma subtypes, highlighting its potential clinical value.
In Vivo Gene Editing Progress
The company is advancing its in vivo gene editing platform, with lead candidates CTX310™ and CTX320™ currently in Phase 1 clinical trials. These therapies target ANGPTL3 and LPA, respectively, and aim to treat genetically driven cardiovascular diseases such as familial hypercholesterolemia and elevated lipoprotein(a). Clinical updates for both programs are anticipated in the first half of 2025. Additionally, CRISPR Therapeutics is developing CTX340™ and CTX450™ for refractory hypertension and acute hepatic porphyrias, respectively, with IND-enabling studies ongoing and clinical trials expected to commence in late 2025.
Strategic Collaborations and Global Reach
In an effort to expand its global footprint, CRISPR Therapeutics formed a strategic partnership with Nkure Therapeutics Private Limited to co-develop and commercialize CTX112 in India. This partnership aligns with the company’s broader objective of addressing unmet medical needs in emerging markets and leveraging the cost-effectiveness of its allogeneic CAR T-cell therapy platform. The collaboration underscores the potential scalability and international applicability of its immuno-oncology pipeline.
Regenerative Medicine and Innovation in Type 1 Diabetes
The regenerative medicine program is progressing with the ongoing clinical evaluation of CTX211, a gene-edited, stem cell-derived beta islet cell precursor therapy for Type 1 diabetes. This program aims to eliminate the need for chronic immunosuppression and restore insulin independence in patients. Next-generation candidates are also under development, with an update expected later in 2025. The company’s continued focus on innovative, cell-based regenerative therapies supports its long-term strategy of tackling complex chronic diseases.
Financial Overview and Operational Efficiency
CRISPR Therapeutics ended 2024 with a strong financial position, holding approximately $1.9 billion in cash, cash equivalents, and marketable securities—an increase from $1.7 billion at the end of 2023. This was supported by a $280 million registered direct offering, milestone payments from Vertex Pharmaceuticals, and other financing activities. R&D expenses decreased year-over-year in Q4 2024 to $82.2 million (from $95.1 million), primarily due to lower external manufacturing costs. However, the company reported a net loss of $37.3 million in Q4 2024, a reversal from a net income of $89.3 million in Q4 2023.
Technical Commentary:
CRSP's stock price has found support at crucial levels and is drifting higher, suggesting a potential upward reversal. The 14-day Relative Strength Index (RSI) is turning around from lower levels, reinforcing a positive outlook. Moreover, the stock is on the brink of reclaiming its 21-period simple moving average, which further supports the bullish sentiment.
As per the above-mentioned price action, recent key business and financial updates, momentum in the stock over the last month, and technical indicators analysis, a ‘Speculative Buy’ rating has been given to CRISPR Therapeutics AG (NASDAQ: CRSP) at its current market price of USD 35.91 as of April 11, 2025 (7:10 am PDT).
Data Powered by EOD Historical Data (“EODHD”).
Sector: Healthcare Industry: Biotechnology
| Company | Change (USD) | Price (USD) | Trailing PE (x) | Forward PE (x) | Price Sales TTM (x) | Price to Book Value (x) | Enterprise Value to Revenue (x) | Enterprise Value to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| CRSP Crispr Therapeutics AG |
0.12 0.31% | 39.35 | - | 23.36 | 17.06 | 1.78 | 8.76 | 14.16 |
| NVO Novo Nordisk A/S |
1.49 2.49% | 61.40 | 41.58 | 31.15 | 2.13 | 32.99 | 2.11 | 4.70 |
| NONOF Novo Nordisk A/S |
1.25 2.05% | 62.25 | 41.06 | 31.25 | 2.08 | 33.11 | 2.11 | 4.70 |
| VRTX Vertex Pharmaceuticals Inc |
1.31 0.27% | 491.78 | 29.67 | 24.33 | 10.38 | 5.83 | 9.33 | 20.00 |
| REGN Regeneron Pharmaceuticals Inc |
2.20 0.38% | 587.69 | 29.07 | 20.12 | 7.57 | 3.82 | 6.95 | 19.42 |
Data Powered by EOD Historical Data (“EODHD”).
Markets are trading in a highly volatile zone currently due to certain macro-economic issues and prevailing geopolitical tensions. Therefore, it is prudent to follow a cautious approach while investing.
Related Risk: This report may be looked at from a high-risk perspective and a recommendation is provided for a short duration. This report is solely based on technical parameters, and the fundamental performance of the stocks has not been considered in the decision-making process. Other factors which could impact the stock prices include market risks, regulatory risks, interest rates risks, currency risks, social and political instability risks etc.
Support: A level at which the stock prices tend to find support if they are falling, and a downtrend may take a pause backed by demand or buying interest. Support 1 refers to the nearby support level for the stock and if the price breaches the level, then Support 2 may act as the crucial support level for the stock.
Target: A level at which the stock prices tend to find resistance when they are rising, and an uptrend may take a pause due to profit booking or selling interest. Target 1 refers to the nearby resistance level for the stock and if the price surpasses the level, then Target 2 may act as the crucial resistance level for the stock.
Stop-loss: It is a level to protect further losses in case of unfavourable movement in the stock prices.
Disclaimer :
This report has been issued by StockNextt which has an Ontario Business Identification Number 1000958347 and British Columbia registration Number FM1051529 is a trade name under Kalkine Canada Advisory Services Inc. having Business Number 761925130BC0001. Kalkine Canada Advisory Services Inc. and StockNextt are collectively referred to as “StockNextt”, “we”, “us”, and “our”. The website https://stocknextt.com and associated pages are published by StockNextt. The information in this report and on the StockNextt website has been prepared from a wide variety of sources, which StockNextt, to the best of its knowledge and belief, considers accurate. StcokNextt has made every effort to ensure the reliability of information contained in its reports, newsletters, and websites. All information represents our views at the date of publication and may change without notice. The information in this report does not constitute an offer to sell securities or other financial products or a solicitation of an offer to buy securities or other financial products. Our reports contain general recommendations for investing in securities and other financial products. StockNextt does not offer financial advice based upon your personal financial situation or goals, and we shall not be held liable for any investment or trading losses you may incur by using the opinions expressed in our reports, publications, market updates, news alerts and corporate profiles. StockNextt does not intend to exclude any liability which it is not permitted to exclude under applicable law or regulation. StockNextt’s general advice does not in any way endorse or recommend individuals, investment products or services for your personal financial situation. You should discuss your portfolios and the risk tolerance level appropriate for your personal financial situation, with a professional authorised financial planner and adviser. You should be aware that the value of any investment and the income from it can go down as well as up and you may not get back the amount invested. Please also read our Terms and conditions for further information. Employees and/or associates of StockNextt and its related entities may hold an interest in the securities or other financial products covered in this report or on the StockNextt website. Any such employees and associates are required to comply with certain safeguards, procedures and disclosures as required by law.
Copyright © 2023 Krish Capital Pty Ltd. All rights reserved. No part of this website, or its content, may be reproduced in any form without our prior consent.
